- active not recruiting
The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema
The SPECTRUM Study is looking at how well a new eye medicine called aflibercept 8 mg works for vision problems caused by wet AMD or diabetic macular oedema. Researchers will collect information from patients who are already prescribed this medicine by their doctor.
Australia · Canada · Denmark - active not recruitingPHASE4
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
This study is looking at a new treatment called faricimab for a common eye condition called 'wet' Age-related Macular Degeneration (AMD). It aims to see how well it works, if it's safe, and how long its effects last when given less often.
United States · Australia · Canada - active not recruitingPHASE3
A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
This study looks at a new way to treat a common eye condition called 'wet' Age-related Macular Degeneration (nAMD). It tests how well a special eye implant works, which slowly releases medicine over a long time, compared to standard eye injections.
Argentina · Australia · Austria - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Clinical Trial to Compare Efficacy, Safety, Tolerability and Immunogenicity of RBS-001 to Eylea® in Subjects with Neovascular Age-Related Macular Degeneration
This study is looking into a new treatment, RBS-001, for a specific eye condition called wet age-related macular degeneration (wet AMD). It compares RBS-001 with an existing treatment, Eylea, to see if it works as well or better, and if it's safe for patients.
Bulgaria · Croatia · Slovakia - ongoing, recruitingTherapeutic use (Phase IV)
(22578) An open-label, non-randomized, multi-center, phase 4 pharmacokinetic study to evaluate the systemic exposure after bilateral intravitreal administration of high dose (8 mg) aflibercept in adults with diabetic macular edema or neovascular age-related macular degeneration
This study is looking at how a higher dose of a medicine called Eylea (aflibercept) works in people with wet age-related macular degeneration or diabetic macular oedema. It wants to see how much of the medicine gets into the body after it's injected into both eyes.
Czechia · Slovakia · Hungary - recruitingPHASE3
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
This study is for people with wet macular degeneration, a common eye condition. It's testing a new, single injection treatment (4D-150) against a standard treatment (Eylea) to see if it can help improve or maintain vision. The goal is to find a longer-lasting solution.
United States · Argentina · Australia